XML 71 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - USD ($)
$ in Millions
Jan. 31, 2024
Oct. 31, 2023
Jan. 31, 2023
Oct. 31, 2022
Liabilities        
Contingent Consideration $ 1 $ 1 $ 3 $ 67
Fair Value, Measurements, Recurring        
Assets        
Total assets measured at fair value 1,181 1,075    
Liabilities        
Total liabilities measured at fair value 49 39    
Fair Value, Measurements, Recurring | Other Current Assets        
Assets        
Cash equivalents (money market funds) 1,102 994    
Derivative instruments (foreign exchange contracts) 12 19    
Fair Value, Measurements, Recurring | Other assets        
Assets        
Trading securities 38 36    
Other investments 29 26    
Fair Value, Measurements, Recurring | Other accrued liabilities        
Liabilities        
Derivative instruments (foreign exchange contracts) 10 2    
Contingent Consideration 1 1    
Fair Value, Measurements, Recurring | Other long-term liabilities        
Liabilities        
Deferred compensation liability 38 36    
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)        
Assets        
Total assets measured at fair value 1,140 1,030    
Liabilities        
Total liabilities measured at fair value 0 0    
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Current Assets        
Assets        
Cash equivalents (money market funds) 1,102 994    
Derivative instruments (foreign exchange contracts) 0 0    
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other assets        
Assets        
Trading securities 38 36    
Other investments 0 0    
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other accrued liabilities        
Liabilities        
Derivative instruments (foreign exchange contracts) 0 0    
Contingent Consideration 0 0    
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other long-term liabilities        
Liabilities        
Deferred compensation liability 0 0    
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)        
Assets        
Total assets measured at fair value 41 45    
Liabilities        
Total liabilities measured at fair value 48 38    
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other Current Assets        
Assets        
Cash equivalents (money market funds) 0 0    
Derivative instruments (foreign exchange contracts) 12 19    
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other assets        
Assets        
Trading securities 0 0    
Other investments 29 26    
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other accrued liabilities        
Liabilities        
Derivative instruments (foreign exchange contracts) 10 2    
Contingent Consideration 0 0    
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other long-term liabilities        
Liabilities        
Deferred compensation liability 38 36    
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)        
Assets        
Total assets measured at fair value 0 0    
Liabilities        
Total liabilities measured at fair value 1 1    
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other Current Assets        
Assets        
Cash equivalents (money market funds) 0 0    
Derivative instruments (foreign exchange contracts) 0 0    
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other assets        
Assets        
Trading securities 0 0    
Other investments 0 0    
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other accrued liabilities        
Liabilities        
Derivative instruments (foreign exchange contracts) 0 0    
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other accrued liabilities | Resolution Bioscience, Inc.        
Liabilities        
Contingent Consideration 1 1    
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other long-term liabilities        
Liabilities        
Deferred compensation liability $ 0 $ 0